Results were presented recently at the 79th Scientific Sessions of the American Diabetes Association.
Medicare beneficiaries who had both diabetes and nonalcoholic fatty liver disease (NAFLD) or a more advanced version of inflammation and fat buildup, known as nonalcoholic steatohepatitis (NASH), had 2 times the mortality rate of the general population, according to data presented last week at the 79th Scientific Sessions of the American Diabetes Association (ADA).
The Global Liver Institute is raising awareness about NAFLD and NASH, and Wednesday marked the second International NASH Day. Both NAFLD and NASH are increasing worldwide with the increased prevalence of obesity, which now affects more than 650 billion people.
The economic costs of NAFLD and NASH are high—slightly more than $1 trillion per year in the United States alone. The implications are important for Medicare, since the diseases are becoming the leading cause of liver transplant in the United States.
Diagnosis of NASH is difficult, as a definitive diagnosis requires a liver biopsy. However, Quest Diagnostics has developed the NAFLD Fibrosis Score Panel, a noninvasive tool to identify patients whose disease has progressed to liver fibrosis.
In the study presented at ADA, those with both diabetes and NAFLD/NASH had an overall mortality rate of 25.1%, compared with the expected rate of 12.7% over the 8-year study period. Researchers used a 20% sample of Medicare beneficiaries from 2007 to 2015, identifying patients with International Statistical Classification of Diseases and Related Health Problems (ICD) and medication codes.
The study identified 100,098 patients with NALFD/NASH, 2520 with compensated cirrhosis, 45,881 with decompensated cirrhosis, 408 with a liver transplant and 284 with hepatocellular carcinoma. Comorbidities were common—at least 71% had cardiovascular disease.
The relationship among diabetes and cardiovascular disease is seen among many patients who develop NAFLD. Preventing progression through weight loss and other steps represents the best approach so far, since efforts to find a treatment have not succeeded.
Mortality rates in 1 year were:
Liver disease progression was higher in those with compensated cirrhosis with diabetes compared to those without diabetes (20% vs 17%).
Reference
Loomba R, Fraysse J, Li S, Ozbay AB, Harrison SA. High risk of mortality and disease progression associated with diabetes mellitus (DM) and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) in Medicare patients. Presented at: 79th Scientific Sessions of the American Diabetes Association; San Francisco, California; June 7-12, 2019. Abstract number 1450-P.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen